You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,098,373

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,098,373

Title:	IL-18 transgenic animal
Abstract:	Transgenic non-human mammals comprising a DNA with an exogenous IL-18 gene incorporated in it such that the exogenous IL-18 gene is skin-specifically expressed, or their offsprings. The transgenic non-human mammals according to the present invention spontaneously develop atopic dermatitis under specific pathogen-free conditions, and therefore, are useful as disease model animals. Use of the transgenic non-human mammals according to the present invention makes it possible to develop drugs for preventing or treating atopic dermatitis by natural immunity and also to elucidate the onset mechanisms of atopic diseases.
Inventor(s):	Mizutani; Hitoshi (Tsui-shi Mie, JP)
Assignee:	Mizutani; Hitoshi (Tsu, JP) Nakanishi; Kenji (Takarazuka, JP) Taiho Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:	10/482,662
Patent Claims:	1. A transgenic mouse whose genome contains an exogenous polynucleotide encoding murine IL-18 operably linked to a mammalian skin-specific promoter, wherein said exogenous polynucleotide expresses murine IL-18 specifically in the skin of said transgenic mouse, and wherein said transgenic mouse exhibits at least one symptom of atopic dermatitis. 2. The transgenic mouse of claim 1, wherein the polynucleotide encoding murine IL-18 encodes mature IL-18. 3. The transgenic mouse of claim 1, wherein the polynucleotide encoding murine IL-18 encodes mouse precursor IL-18. 4. The transgenic mouse of claim 1, wherein said mammalian promoter is a human involucrin promoter. 5. The transgenic mouse of claim 1, wherein mammalian promoter is a keratin promoter. 6. The transgenic mouse of claim 1, wherein said keratin promoter is a promoter for keratin 1, 5, 10 or 14. 7. The transgenic mouse of claim 1, wherein said exogenous polynucleotide comprises in the following order: mammalian K14 promoter, .beta.-globin intron, PTH-mIL-18 and K14 polyA. 8. The transgenic mouse of claim 1, wherein said symptom is lichenified dermatitis. 9. The transgenic mouse of claim 1, wherein said symptom is erosive dermatitis. 10. The transgenic mouse of claim 1, wherein said symptom is inflammation associated with hyperkeratosis or acanthosis on the thick epidermis around an ulcer. 11. The transgenic mouse of claim 1, which continuously develops atopic dermatitis. 12. The transgenic mouse of claim 1, which continuously secretes IL-18 into the blood. 13. A screening method for identifying a substance that can prevent or treat atopic dermatitis comprising administering said substance to the transgenic mouse of claim 1 and determining whether a symptom of atopic dermatitis is ameliorated or prevented or determining the level(s) of IgE or histamine, or both, in the mouse. 14. The method of claim 13, wherein said substance is administered to said transgenic mouse under pathogen-free conditions. 15. The method of claim 13, wherein determining whether a symptom of atopic dermatitis has been ameliorated or prevented comprises measuring the level of mature IL-18 in the blood, detecting mature IL-18 in the skin, visual observation, microscopic observation of skin tissue, or measuring the histamine level in the blood. 16. The method of claim 13, comprising determining the level(s) of IgE or histamine, or both, in the mouse. 17. A method of making the transgenic mouse of claim 1 comprising: a) introducing an exogenous polynucleotide comprising a murine IL-18 operably linked to a mammalian skin-specific promoter into a fertilized mouse egg, b) implanting said egg into a female mouse under conditions suitable for gestation of a transgenic mouse, and c) identifying a transgenic mouse exhibiting skin-specific expression of murine IL-18, wherein said transgenic mouse exhibits at least one symptom of atopic dermatitis. 18. A transgenic mouse whose genome contains an exogenous polynucleotide encoding murine IL-18 operably linked to a mammalian skin-specific promoter and a parathyroid leader sequence, wherein said exogenous polynucleotide expresses murine IL-18 specifically in the skin of said transgenic mouse, and wherein said transgenic mouse exhibits at least one symptom of atopic dermatitis. 19. The transgenic mouse of claim 18, wherein the mammalian skin-specific promoter is a keratin promoter.

Details for Patent 7,098,373

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2021-07-12
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2021-07-12
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2021-07-12
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924	⤷ Try a Trial	2021-07-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.